Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) had its price objective reduced by stock analysts at Wells Fargo & Company from $105.00 to $98.00 in a research note issued on Wednesday, Stock Target Advisor reports. The firm presently has an "overweight" rating on the biotechnology company's stock. Wells Fargo & Company's target price suggests a potential upside of 475.46% from the company's previous close.
Other analysts have also recently issued reports about the company. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Monday, May 9th. Robert W. Baird upgraded Arcturus Therapeutics from an "underperform" rating to a "neutral" rating and cut their target price for the stock from $21.00 to $18.00 in a research report on Wednesday, May 11th. Raymond James cut Arcturus Therapeutics from a "market perform" rating to an "underperform" rating in a research report on Wednesday. The Goldman Sachs Group lowered their price target on Arcturus Therapeutics from $14.00 to $8.00 and set a "sell" rating on the stock in a report on Tuesday, May 24th. Finally, Citigroup lowered Arcturus Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the stock from $86.00 to $29.00 in a report on Thursday, April 21st. Four research analysts have rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $38.75.Get Arcturus Therapeutics alerts:
Arcturus Therapeutics Trading Down 2.6 %
ARCT opened at $17.03 on Wednesday. The firm has a market cap of $449.92 million, a P/E ratio of -2.71 and a beta of 2.70. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.21. Arcturus Therapeutics has a 52 week low of $11.70 and a 52 week high of $58.45. The business has a fifty day simple moving average of $17.06 and a 200-day simple moving average of $20.65.Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) last posted its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts' consensus estimates of ($1.90) by $1.08. Arcturus Therapeutics had a negative return on equity of 73.87% and a negative net margin of 407.91%. The company had revenue of $27.09 million for the quarter, compared to analysts' expectations of $3.33 million. During the same period last year, the firm earned ($2.07) earnings per share. On average, equities analysts expect that Arcturus Therapeutics will post -6.71 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at $32,000. KRS Capital Management LLC purchased a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at $51,000. Amalgamated Bank purchased a new stake in shares of Arcturus Therapeutics during the 1st quarter valued at $69,000. Byrne Asset Management LLC purchased a new stake in shares of Arcturus Therapeutics during the 4th quarter valued at $114,000. Finally, Daiwa Securities Group Inc. grew its stake in shares of Arcturus Therapeutics by 44.0% during the 1st quarter. Daiwa Securities Group Inc. now owns 3,503 shares of the biotechnology company's stock valued at $94,000 after buying an additional 1,071 shares during the period. 80.10% of the stock is currently owned by institutional investors and hedge funds.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.
- Get a free copy of the StockNews.com research report on Arcturus Therapeutics (ARCT)
- Look at Honeywell for a Steady and Diversified Stock
- Why Invest in High-Yield Dividend Stocks?
- Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
- Find and Profitably Trade Stocks at 52-Week Lows
- Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.